NCT06234345View on ClinicalTrials.gov

Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR)

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

1,252

Participants

Timeline

Start Date

September 30, 2026

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2028

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Fluticasone 250mcg/Formoterol 12mcg/Glycopyrronium 25mcg

Participants randomized to this group will receive 1 capsule per inhalation twice a day

DRUG

Comparator - Trimbow®

Participants randomized to this group will receive 2 triggering twice a day

Trial Locations (1)

06696-000

Eurofarma Laboratorios S.A, São Paulo

Sponsors
All Listed Sponsors
lead

Eurofarma Laboratorios S.A.

INDUSTRY